aripiprazole has been researched along with buspirone in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Sen, S; Sinha, N | 1 |
| Chang, G; Di, L; Huang, Y; Lin, Z; Liston, TE; Scott, DO; Troutman, MD; Umland, JP | 1 |
| Ballard, TE; Henderson, JL; Kalgutkar, AS; Obach, RS; Orr, ST; Ripp, SL; Scott, DO; Sun, H | 1 |
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jaśkowska, J; Kułaga, D; Satała, G | 1 |
| Jaśkowska, J; Kowalski, P | 1 |
| Frisch, J; Hiemke, C; Holthoewer, D; Kirschbaum, KM; Schmitt, U | 1 |
2 review(s) available for aripiprazole and buspirone
| Article | Year |
|---|---|
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
Topics: Animals; Apoproteins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Drug Interactions; Heme; Humans; Models, Biological; Pharmacokinetics; Structure-Activity Relationship; Time Factors | 2012 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
7 other study(ies) available for aripiprazole and buspirone
| Article | Year |
|---|---|
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Species independence in brain tissue binding using brain homogenates.
Topics: Animals; Brain; Dogs; Guinea Pigs; Humans; Macaca fascicularis; Mice; Rats; Species Specificity | 2011 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
Design, synthesis and biological evaluation of novel serotonin and dopamine receptor ligands being 6-bromohexyl saccharine derivatives.
Topics: Antidepressive Agents; Binding Sites; Dopamine Antagonists; Drug Evaluation, Preclinical; Ligands; Models, Molecular; Molecular Structure; Piperazines; Protein Binding; Receptors, Dopamine; Receptors, Serotonin; Saccharin; Serotonin; Serotonin Antagonists; Structure-Activity Relationship; Thermodynamics | 2019 |
An efficient synthesis of aripiprazole, buspirone and NAN-190 by the reductive alkylation of amines procedure.
Topics: Alkylation; Amines; Aripiprazole; Buspirone; Chemistry Techniques, Synthetic; Chromatography, High Pressure Liquid; Hydrolysis; Molecular Structure; Oxidation-Reduction; Piperazines; Quinolones; Spectrometry, Mass, Electrospray Ionization | 2012 |
Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties.
Topics: Animals; Antipsychotic Agents; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B, Member 1; Buspirone; Haloperidol; Ketanserin; Male; Mice; Mice, Knockout; Motor Activity; Piperazines; Quinolones; Rotarod Performance Test; Serotonin Antagonists; Serotonin Receptor Agonists; Thiazoles | 2013 |